Earnings History Data for Rhythm Pharmaceuticals, Inc. (RYTM) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company. It focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies which result in life-threatening metabolic disorders. The Company's product candidate principally consists of setmelanotide, a potent, first-in-class melanocortin-4 receptor or MC4R, agonist for the treatment of rare genetic disorders of obesity. Rhythm Pharmaceuticals, Inc. is based in Boston, MA.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
05-11-2024	AH		RYTM	Rhythm Pharmaceuticals, Inc.	2,920	-0.73	-0.80	-0.76	Rhythm Pharmaceuticals GAAP EPS of -$0.73 beats by $0.08, revenue of $33.25M beats by $0.78M [11/5/2024 4:04 PM]	62.70	6.45 (11.47%)	59.00	2.75 (4.89%)	23.83 - 64.73	2,451,099	410,000	1,883
Rhythm Pharmaceuticals GAAP EPS of -$0.73 beats by $0.08, revenue of $33.25M beats by $0.78M [11/5/2024 4:04 PM] Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update [2024-11-05 04:01PM] Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek 2024 [Nov-04-24 04:01PM] Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences [2024-11-06 08:00AM] Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates [Nov-05-24 05:10PM]
06-08-2024	PM		RYTM	Rhythm Pharmaceuticals, Inc.	2,860	-0.55	-0.70	-0.82	Rhythm Pharmaceuticals GAAP EPS of -$0.55 beats by $0.15, revenue of $29.08M beats by $0.29M [8/6/2024 7:08 AM]	44.04	0.01 (0.02%)	44.04	0.0 (0.00%)	20.97 - 53.92	448,124	470,000	9,632
Rhythm Pharmaceuticals Q2 2024 Earnings Preview [8/5/2024 12:18 PM] Rhythm Pharmaceuticals GAAP EPS of -$0.55 beats by $0.15, revenue of $29.08M beats by $0.29M [8/6/2024 7:08 AM]
07-05-2024	PM		RYTM	Rhythm Pharmaceuticals	2,499	-2.35	-2.12	0.00	Rhythm Pharmaceuticals GAAP EPS of -$2.35 misses by $0.33, revenue of $25.97M misses by $0.93M [5/7/2024 7:20 AM]	39.34	-4.54 (-10.34%)	38.97	-4.91 (-11.19%)	15.50 - 52.57	1,148,789	580,000	1,796
Rhythm Pharmaceuticals GAAP EPS of -$2.35 misses by $0.33, revenue of $25.97M misses by $0.93M [5/7/2024 7:20 AM] Rhythm Pharmaceuticals Q1 2024 Earnings Preview [5/6/2024 10:59 AM]
22-02-2024	PM		RYTM	Rhythm Pharmaceuticals, Inc.	2,910	-0.70	-0.70	-0.75	Rhythm Pharmaceuticals reports mixed Q4 results; initiates FY24 outlook [2/22/2024 7:15 AM]	44.03	-4.78 (-9.79%)	0.0	0.0 (0.00%)	15.50 - 52.57	1,129,228	590,000	0
Rhythm Pharmaceuticals Q4 2023 Earnings Preview [2/21/2024 11:01 AM] Rhythm Pharmaceuticals reports mixed Q4 results; initiates FY24 outlook [2/22/2024 7:15 AM]
07-11-2023	PM		RYTM	Rhythm Pharmaceuticals, Inc.	1,530	-0.76	-0.76	-0.79	Rhythm Pharmaceuticals GAAP EPS of -$0.76 in-line, revenue of $22.5M beats by $0.32M [11/7/2023 7:08 AM]	26.90	-0.19 (-0.70%)	0.0	0.0 (0.00%)	15.50 - 34.99	931,229	540,000	0
Rhythm Pharmaceuticals Q3 2023 Earnings Preview [11/6/2023 2:46 PM] Rhythm Pharmaceuticals GAAP EPS of -$0.76 in-line, revenue of $22.5M beats by $0.32M [11/7/2023 7:08 AM]
01-08-2023	PM		RYTM	Rhythm Pharmaceuticals, Inc.	1,020	-0.82	-0.81	-0.89	Rhythm Pharmaceuticals GAAP EPS of -$0.82 misses by $0.04, revenue of $19.22M beats by $4.19M [8/1/2023 7:14 AM]	22.76	4.92 (27.58%)	19.43	1.59 (8.91%)	12.18 - 34.99	3,205,064	490,000	7,062
Rhythm Pharmaceuticals Q2 2023 Earnings Preview [7/31/2023 2:51 PM] Rhythm Pharmaceuticals GAAP EPS of -$0.82 misses by $0.04, revenue of $19.22M beats by $4.19M [8/1/2023 7:14 AM] Rhythm Pharma surges on strong Q2 sales; BofA upgrades [8/1/2023 2:47 PM]
02-05-2023	PM	7:00 AM ET (May 2)	RYTM	Rhythm Pharmaceuticals, Inc.	1,130	-0.92	-0.71	-1.05	Rhythm Pharmaceuticals reports misses Q1 top and bottom consensus; reaffirms FY23 outlook [5/2/2023 7:15 AM]	18.76	-1.45 (-7.17%)	0.0	0.0 (0.00%)	3.04 - 34.99	2,164,386	560,000	0
Rhythm Pharmaceuticals reports misses Q1 top and bottom consensus; reaffirms FY23 outlook [5/2/2023 7:15 AM]
01-03-2023	PM	7:00 AM ET (Mar 1)	RYTM	Rhythm Pharmaceuticals, Inc.	1,430	-0.75	-0.82	-0.85	Rhythm Pharmaceuticals beats Q4 top and bottom line estimates; initiates FY23 outlook [3/1/2023 7:08 AM]	25.76	1.45 (5.96%)	0.0	0.0 (0.00%)	3.04 - 34.99	1,855,546	440,000	0
Rhythm Pharmaceuticals Q4 2022 Earnings Preview [2/28/2023 12:41 PM] Rhythm Pharmaceuticals beats Q4 top and bottom line estimates; initiates FY23 outlook [3/1/2023 7:08 AM]
02-08-2022	PM	7:00 AM ET (Aug 2)	RYTM	Rhythm Pharmaceuticals, Inc.	663.18	-0.89	-0.79	-0.70	Rhythm Pharmaceuticals GAAP EPS of -$0.89 beats by $0.06, revenue of $2.31M misses by $0.26M [8/2/2022 7:09 AM]	14.15	1.70 (13.65%)	12.80	0.35 (2.81%)	3.04 - 18.06	4,044,853	3,290,000	2,565
Rhythm Pharmaceuticals Q2 2022 Earnings Preview [8/1/2022 1:27 PM] Rhythm Pharmaceuticals GAAP EPS of -$0.89 beats by $0.06, revenue of $2.31M misses by $0.26M [8/2/2022 7:09 AM] Rhythm Pharma stock surges 21% on higher Q2 license revenue, genetic disorder drug Imcivree sales [8/2/2022 11:11 AM]
03-05-2022	PM	7:00 AM ET (May 3)	RYTM	Rhythm Pharmaceuticals	335.00	-1.05	-0.98	0.00	Rhythm Pharmaceuticals GAAP EPS of -$1.05 misses by $0.04, revenue of $1.49M [5/3/2022 7:31 AM]	6.14	-0.16 (-2.54%)	6.30	0.0 (0.00%)	5.95 - 23.05	250,825	270,000	89,483
Rhythm Pharmaceuticals Q1 2022 Earnings Preview [5/2/2022 12:49 PM] Rhythm Pharmaceuticals GAAP EPS of -$1.05 misses by $0.04, revenue of $1.49M [5/3/2022 7:31 AM] Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting [May-02-22 08:00AM] Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates [May-03-22 08:15AM] Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update [May-03-22 07:00AM]
01-03-2022	PM	7:00 AM ET (Mar 1)	RYTM	Rhythm Pharmaceuticals, Inc.	373.49	-0.85	1.00	-0.79	Rhythm Pharmaceuticals GAAP EPS of -$0.85 beats by $0.06, revenue of $1.82M beats by $0.12M [3/1/2022 7:14 AM]	8.37	0.75 (9.84%)	7.62	0.0 (0.00%)	6.01 - 28.79	478,442	930,000	189,422
Rhythm Pharmaceuticals Q4 2021 Earnings Preview [2/28/2022 1:46 PM] Rhythm Pharmaceuticals GAAP EPS of -$0.85 beats by $0.06, revenue of $1.82M beats by $0.12M [3/1/2022 7:14 AM] Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results [Mar-01-22 07:00AM] Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue Estimates [Mar-01-22 08:15AM] Rhythm Pharmaceuticals to Present at Cowen & Co. 42nd Annual Health Care Conference [Mar-01-22 04:01PM]
02-11-2021	PM	7:00 AM ET (Nov 2)	RYTM	Rhythm Pharmaceuticals, Inc.	599.72	-0.70	-0.83	-0.77	Rhythm Pharmaceuticals EPS beats by $0.10, beats on revenue [11/2/2021 7:02 AM]	12.90	0.80 (6.61%)	12.90	0.0 (0.00%)	10.70 - 43.26	319,776	340,000	4,512
Rhythm Pharmaceuticals Q3 2021 Earnings Preview [11/1/2021 1:53 PM] Rhythm Pharmaceuticals EPS beats by $0.10, beats on revenue [11/2/2021 7:02 AM] Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients Living with Bardet-Biedl Syndrome at ObesityWeek® 2021 [Nov-01-21 04:01PM] Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results [Nov-02-21 07:00AM]
03-08-2021	PM	8:00 AM ET (Aug 3)	RYTM	Rhythm Pharmaceuticals, Inc.	868.07	-0.70	-0.80	-0.71	Rhythm Pharmaceuticals EPS in-line, misses on revenue [8/3/2021 7:16 AM]	16.63	-0.79 (-4.53%)	17.42	0.0 (0.00%)	16.16 - 43.26	653,953	290,000	1,365
Rhythm Pharmaceuticals EPS in-line, misses on revenue [8/3/2021 7:16 AM] Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results [Aug-03-21 07:01AM] Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity [Aug-03-21 06:59AM]
03-05-2021	PM		RYTM	Rhythm Pharmaceuticals, Inc.	1,030	0.90	-0.02	-0.78	Rhythm Pharmaceuticals EPS beats by $0.62, misses on revenue [5/3/2021 8:26 AM]	22.03	0.47 (2.18%)	21.56	0.0 (0.00%)	17.27 - 43.26	201,783	300,000	3,859
Rhythm Pharmaceuticals EPS beats by $0.62, misses on revenue [5/3/2021 8:26 AM] Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results [May-03-21 08:00AM] Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass Estimates [May-03-21 10:55AM]
01-03-2021	PM		RYTM	Rhythm Pharmaceuticals, Inc.	1,340	-0.79	-0.81	-0.78	Rhythm Pharmaceuticals reports Q4 results [3/1/2021 8:56 AM]	26.88	0.96 (3.70%)	25.92	0.0 (0.00%)	12.99 - 43.26	291,008	428,061	19,274
Rhythm Pharmaceuticals reports Q4 results [3/1/2021 8:56 AM]
03-08-2020	PM	8:00 AM ET (Aug 3)	RYTM	Rhythm Pharmaceuticals, Inc.	877.87	-0.71	-0.83	-1.24	Rhythm Pharmaceuticals EPS beats by $0.12 [8/3/2020 8:09 AM]	19.35	-0.85 (-4.21%)	20.20	0.0 (0.00%)	12.99 - 25.86	42,128	141,295	10,661